Alpha 2.0
Login Register
» Authors » Marcel P M Stokkel

Marcel P M Stokkel

Explore the profile of Marcel P M Stokkel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 117
Citations 1724
Followers 0
Related Specialties
Nuclear Medicine
Radiology
Oncology
Top 10 Co-Authors
Jeroen J Bax
Else A Aalbersberg
Bernies van der Hiel
Ernst E van der Wall
Petra Dibbets-Schneider
Berlinda J de Wit-van der Veen
Marie-Jeanne T F D Vrancken Peeters
Linda J de Wit-van der Veen
Albert de Roos
Martin J Schalij
Published In
Clin Nucl Med
Eur J Nucl Med Mol Imaging
Nucl Med Commun
J Nucl Med
EJNMMI Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Novel Clinical PET Tracers in the Pipeline for Melanoma
Jaber N, Saadani H, Schats W, Aalbersberg E, Stokkel M
Curr Oncol Rep . 2025 Mar; PMID: 40072700
Purpose: The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current...
2.
Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol
van Hemert A, van Loevezijn A, Baas M, Stokkel M, Groen E, van der Noort V, et al.
Breast . 2025 Feb; 80:104411. PMID: 39954569
Purpose: Axillary lymph node staging techniques after primary systemic therapy (PST) show low false negative rates, stimulating the omission of axillary lymph node dissection (ALND). Breast cancer patients with extensive...
3.
The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy
Gunster J, van Duijnhoven F, Scholten A, Smorenburg C, Dezentje V, van Olmen J, et al.
Breast Cancer Res Treat . 2024 Sep; 209(1):117-124. PMID: 39327358
Purpose: This study aims to identify which breast cancer patients benefit from the routine use of FDG-PET/CT in a large cohort of patients scheduled for neoadjuvant systemic therapy (NST). Methods:...
4.
Lanreotide versus placebo for tumour reduction in patients with a Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment
Boertien T, Drent M, Booij J, Majoie C, Stokkel M, Hoogmoed J, et al.
Lancet Reg Health Eur . 2024 Jul; 42:100923. PMID: 39070749
Background: No established medical treatment options currently exist for patients with non-functioning pituitary macroadenoma (NFPMA). Somatostatin analogues may prevent tumour growth, but randomised controlled trials are lacking. somatostatin receptor assessment...
5.
Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer
van Olmen J, Schrijver A, Stokkel M, Loo C, Gunster J, Vrancken Peeters M, et al.
Breast Cancer Res Treat . 2024 Jun; 206(3):585-594. PMID: 38864980
Purpose: Breast cancer (BC) patients undergoing FDG-PET/CT scans for neoadjuvant chemotherapy (NAC) may have additional non-BC related findings. The aim of this study is to describe the clinical implications of...
6.
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication
van der Hiel B, Aalbersberg E, van den Eertwegh A, Fischer J, Boellaard R, de Vos F, et al.
Clin Nucl Med . 2024 May; 49(8):722-726. PMID: 38768063
Purpose: This prospective study evaluates the biodistribution of 18 F-FLT PET in patients with advanced melanoma before and after treatment with BRAF/MEK inhibitors. Patients And Methods: Eighteen BRAF-positive unresectable stage...
7.
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors
Hoogenkamp D, de Wit-van der Veen L, Huizing D, Tesselaar M, van Leeuwaarde R, Stokkel M, et al.
Curr Oncol Rep . 2024 Apr; 26(5):551-561. PMID: 38598035
Purpose Of Review: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine...
8.
The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B, Aalbersberg E, van den Eertwegh A, de Wit-van der Veen L, Stokkel M, Lopez-Yurda M, et al.
Clin Nucl Med . 2023 Dec; 49(2):138-145. PMID: 38113329
Purpose: The aims of this study were to investigate whether (early) PERCIST response monitoring with 18 F-FDG PET/CT is predictive for progression-free survival (PFS) in unresectable stage III or IV...
9.
Radio-Guided Occult Lesion Localization With 99m Tc for the Localization of Nonpalpable Melanoma and Soft Tissue Sarcoma Lesions: A Feasibility Study
Reijers S, Mook F, Groen H, Schrage Y, Stokkel M, Donswijk M, et al.
Clin Nucl Med . 2023 Nov; 49(1):23-26. PMID: 37991434
Purpose Of The Report: Localization techniques are needed to facilitate resection of nonpalpable lesions. In this study, the feasibility of radio-guided occult lesion localization (ROLL) with 99m Tc is investigated...
10.
Predicting [Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Siebinga H, de Wit-van der Veen B, Beijnen J, Stokkel M, Dorlo T, Huitema A, et al.
EJNMMI Phys . 2023 Aug; 10(1):48. PMID: 37615812
Background: Prediction of [Lu]Lu-HA-DOTATATE kidney and tumor uptake based on diagnostic [Ga]Ga-HA-DOTATATE imaging would be a crucial step for precision dosing of [Lu]Lu-HA-DOTATATE. In this study, the population pharmacokinetic (PK)...